Summary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022 : recommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults.: HP5-148/2022E-PDF
"On November 3, 2022, Health Canada authorized the use of the Moderna Spikevax 50 mcg BA.4/5 bivalent COVID-19 vaccine as a booster dose in individuals 18 years of age and older"--Overview, page 3.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.916714&sl=0
Department/Agency | Public Health Agency of Canada, issuing body. Canada. National Advisory Committee on Immunization, issuing body. |
---|---|
Title | Summary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022 : recommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults. |
Variant title | Recommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults Summary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022 |
Publication type | Monograph |
Language | [English] |
Other language editions | [French] |
Format | Electronic |
Electronic document | |
Note(s) | Issued also in French under title: Recommandations sur l'utilisation chez les adultes du vaccin de rappel à ARNm Spikevax bivalent BA.4/5 (50 mcg) de Moderna contre la COVID-19 : résumé des mises à jour du Comité consultatif national de l'immunisation (CCNI) du 3 novembre 2022. Cover title. "Pub.: 220546." |
Publishing information | Ottawa, ON : Public Health Agency of Canada = Agence de la santé publique du Canada, 2022. ©2022 |
Description | 1 online resource (3 pages) |
ISBN | 9780660460291 |
Catalogue number |
|
Departmental catalogue number | 220546 |
Subject terms | COVID-19 (Disease) -- Vaccination -- Canada. COVID-19 (Disease) -- Vaccination -- Government policy -- Canada. |